Skip to main content
main-content

30-10-2018 | Colorectal cancer | ESMO 2018 | Video

Nivolumab plus low-dose ipilimumab promising for treatment-naïve MSI-high mCRC

Heinz-Josef Lenz outlines the results of CheckMate-142 study investigating combination immunotherapy in the first-line treatment of patients with MSI-high metastatic colorectal cancer, and discusses the unmet needs of those with MSI-low tumors (5:58).

Please log in to get access to this content